Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology

Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if admini...

Full description

Bibliographic Details
Main Authors: Fabrice Cognasse, Hind Hamzeh-Cognasse, Anne-Claire Duchez, Natalia Shurko, Marie-Ange Eyraud, Charles-Antoine Arthaud, Amélie Prier, Marco Heestermans, Olivier Hequet, Brigitte Bonneaudeau, Sandrine Rochette-Eribon, Françoise Teyssier, Valérie Barlet-Excoffier, Patricia Chavarin, Dominique Legrand, Pascale Richard, Pascal Morel, Nuala Mooney, Pierre Tiberghien
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
COVID-19
convalescent plasma
inflammation
cytokine
endothelial cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1034379/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1034379/full

Similar Items